Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer (vol 18, pg 758, 2012)

被引：0
|
作者：
Sun, Jessica D.
Liu, Qian
Wang, Jingli
Ahluwalia, Dharmendra
Ferraro, Damien
Wang, Yan
Duan, Jian-Xin
Ammons, W. Steve
Curd, John G.
Matteucci, Mark D.
Hart, Charles P.
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 10期
关键词：
D O I：
10.1158/1078-0432.CCR-24-1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2287 / 2287
页数：1
相关论文
共 50 条
  • [31] Combination treatment with hypoxia-activated prodrug TH-302 and radiation reduce pancreatic tumor initiating cells and tumor growth in patient-derived xenografts
    Lohse, Ines
    Rasowski, Joanna
    Cao, Pinjian
    Pintilie, Melania
    Do, Trevor
    Ibrahimov, Emin
    Tsao, Ming-Sound
    Hill, Richard P.
    Hedley, David W.
    CANCER RESEARCH, 2015, 75
  • [32] A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
    Hajj, Carla
    Russell, James
    Hart, Charles P.
    Goodman, Karyn A.
    Lowery, Maeve A.
    Haimovitz-Friedman, Adriana
    Deasy, Joseph O.
    Humm, John L.
    TRANSLATIONAL ONCOLOGY, 2017, 10 (05): : 760 - 765
  • [33] TH-302: A Highly Selective Hypoxia-Activated Prodrug for Treating PARP Inhibitor-Resistant Cancers
    Cheng, Xiaobo
    Xu, Jing
    Meng, Fanying
    Qi, Tianyang
    Wang, Xiaotong
    Chai, Ranran
    Lu, Chong
    Jin, Guanqin
    Zheng, Kewei
    Liu, Xing
    Wang, Yizhi
    Cai, Xiaohong
    Lu, Zhaoqiang
    Yu, Jibing
    Ruan, Meizhen
    Fan, Jinwei
    Qin, Wei
    Huang, Qunhui
    Zhang, Yanjun
    Li, Anrong
    Duan, Jianxin
    Kang, Yu
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2024, 2024
  • [34] Combination treatment with hypoxia-activated prodrug TH-302 and the mTOR inhibitor everolimus results in enhanced antitumor efficacy in preclinical models
    Sun, Jessica D.
    Ahluwalia, Dharmendra
    Liu, Qian
    Wang, Yan
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER RESEARCH, 2012, 72
  • [35] Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
    Huang, Yan
    Tian, Ying
    Zhao, Yuanyuan
    Xue, Cong
    Zhan, Jianhua
    Liu, Lin
    He, Xiaobo
    Zhang, Li
    CANCER COMMUNICATIONS, 2018, 38
  • [36] Enhancement of hypoxia-activated prodrug TH-302 activity by Chk1 inhibition
    Meng, Fanying
    Bhupathi, Deepthi
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER RESEARCH, 2012, 72
  • [37] Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
    Saggar, Jasdeep K.
    Tannock, Ian F.
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2107 - 2114
  • [38] Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
    van der Wiel, Alexander M. A.
    Jackson-Patel, Victoria
    Niemans, Raymon
    Yaromina, Ala
    Liu, Emily
    Marcus, Damienne
    Mowday, Alexandra M.
    Lieuwes, Natasja G.
    Biemans, Rianne
    Lin, Xiaojing
    Fu, Zhe
    Kumara, Sisira
    Jochems, Arthur
    Ashoorzadeh, Amir
    Anderson, Robert F.
    Hicks, Kevin O.
    Bull, Matthew R.
    Abbattista, Maria R.
    Guise, Christopher P.
    Deschoemaeker, Sofie
    Thiolloy, Sophie
    Heyerick, Arne
    Solivio, Morwena J.
    Balbo, Silvia
    Smaill, Jeff B.
    Theys, Jan
    Dubois, Ludwig J.
    Patterson, Adam, V
    Lambin, Philippe
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2372 - 2383
  • [39] TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
    Qian Liu
    Jessica D. Sun
    Jingli Wang
    Dharmendra Ahluwalia
    Amanda F. Baker
    Lee D. Cranmer
    Damien Ferraro
    Yan Wang
    Jian-Xin Duan
    W. Steve Ammons
    John G. Curd
    Mark D. Matteucci
    Charles P. Hart
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1487 - 1498
  • [40] Treatment (Tx) guidelines for skin and mucosal events in patients with solid tumors (pts) receiving TH-302, a tumor selective, hypoxia-activated prodrug.
    Borad, M. J.
    Boyer, N.
    Curd, J. G.
    Sunkara, U. K.
    Awerkamp, K.
    Lacouture, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345